Merck, the New Jersey-based pharmaceutical giant, will pay Cidara stockholders $221.50 a share in the all-cash deal. Cidara ...

Merck agreed to pay $9.2 billion to purchase Cidara Therapeutics, looking to cash in on the firm's experimental flu treatment.

C idara Therapeutics (CDTX) stock rocketed higher on Friday after the biotechnology company announced it will be acquired by ...

Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & ...

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

Merck & Co. Inc. (NYSE: MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ: CDTX) for $221.50 per share in ...

Bidding war goes down to wire for company whose lead drug is potential alternative to vaccines for vulnerable patients ...

Cidara Therapeutics (CDTX) stock surge 100% as Merck acquires biotech for $9.2B at $221.50 per share, triple its previous ...

Merck will pay $221.50 a share in cash for Cidara in a tender offer, more the twice Thursday’s closing price, for a total ...

The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative ...

In a significant move to bolster its pharmaceutical portfolio, Merck announced its acquisition of Cidara Therapeutics for a staggering $9.2 billion. This strategic decision underscores Merck's ...

Wondering if Merck stock is truly a bargain or just priced for perfection? You are not alone. Let's dig into what the numbers ...